Navigation Links
Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer

LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, presented today findings from its novel human-in-mouse (HIM) tissue transgenic cancer model system, in which AVEO successfully created invasive human tumors that develop over time in mice from primary human breast tissue. This model enables scientists, for the first time, to generate and study in vivo, human tumor initiation, progression and treatment in a preclinical model. This groundbreaking model was presented today in a session entitled "Mouse Models of Cancer 6: Signaling Mechanisms in Initiation, Progression and Therapeutics" at the 100th American Association for Cancer Research (AACR) Annual Meeting in Los Angeles, California.

"For decades, human cancer cell line-derived xenografts have been the in vivo models of choice for pre-clinical studies, and with a few notable exceptions, those xenograft models have not been predictive of human clinical efficacy," said Tuan Ha-Ngoc, president and CEO of AVEO Pharmaceuticals. "As a result, clinical development in oncology remains largely empirical, resulting in a greater than 90 percent failure rate and long development timelines with significant capital risk. We believe our HIM model represents the next generation in modeling that will ultimately revolutionize early clinical development."

Murray O. Robinson, PhD, senior vice president of Translational Research at AVEO, added, "One issue with cell line xenografts is that the cell culture conditions for establishing cancer cell lines impart strong selection pressures that are different from those experienced by cells in an in vivo environment. Our proprietary models as part of the Human Response Prediction(TM) Platform provide a defined genetic context as well as an accurate tissue context in which to validat
'"/>




Page: 1 2 3

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:9/22/2014)... CytRx Corporation (Nasdaq: CYTR ), ... today announced that study designs and progress from two ... pivotal global Phase 3 clinical trial in relapsed/refractory soft ... trial in small cell lung cancer, will be presented ... Congress being held September 26-30, in Madrid, ...
(Date:9/22/2014)... Nepstar Chain Drugstore Ltd. (NYSE: NPD ) ("Nepstar" or ... based on the number of directly operated stores, today ... Shareholders (the "AGM") on October 22, 2014 at 10:00 a.m. Beijing ... the Company at 6th Floor, Tower B, Xinnengyuan Building, Nanhai Road, ... 518054, People,s Republic of China . ...
(Date:9/20/2014)... OTTAWA , Sept. 20, 2014 /CNW/ - The issue: ... voluntarily recalling all lots of its Mylan-Nitro Spray 0.4 mg/metered ... is part of the pump component. A ... delivery of nitroglycerin to the patient. This defect may lead ... fact they are unable to access it. Not receiving nitroglycerin ...
Breaking Medicine Technology:CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 22, 2014 2Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2
... ALEXANDRIA, Va., March 1, 2012  The National Community ... campaign launched today by the Pharmaceutical Care Management ... (PBMs). (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ... said NCPA Senior Vice President for Government Affairs John ...
... PARSIPPANY, N.J., March 1, 2012  PDI, Inc. (Nasdaq: ... its fourth quarter and full year 2011 financial results ... and host a conference call on Thursday, March 8, ... information: ,  Date:Thursday, March 8, 2012Time:8:30 am Eastern timeDial-in ...
Cached Medicine Technology:NCPA Blasts Irresponsible Ad by PBM Lobby as an Affront to Fighting Drug Diversion, Pharmacy Crime 2NCPA Blasts Irresponsible Ad by PBM Lobby as an Affront to Fighting Drug Diversion, Pharmacy Crime 3
(Date:9/22/2014)... (PRWEB) September 22, 2014 B. E. ... to healthcare providers, has been retained to lead a ... County-Benson Hospital (SCBH) in Benson, Minn. The top executive ... has recently placed more than 900 healthcare executives into ... serves the residents of Swift County, Benson and the ...
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 ... Beth Schrope , NewYork-Presbyterian/Columbia University Medical Center ... islet surgery, to prevent diabetes in patients who ... first center in the New York metropolitan area ... roughly 87,000 people in the United States receive ...
(Date:9/22/2014)... September 22, 2014 The ... Winter & Alvin has just been released to ... the personal development community. The media attention surrounding ... HonestyFirstReviews.com's Tiffany Hendricks prompting an investigative review. , ... great interest for many entrepreneurs and others interested ...
(Date:9/22/2014)... September 22, 2014 Purchasing greenhouse starter ... helps ensure a positive outcome. Gothic Arch ... making them a leader in the industry and a ... , third generation owner of Gothic Arch Greenhouses, it’s ... needed. Warm, moist, controlled air created inside a greenhouse ...
(Date:9/22/2014)... 22, 2014 One key emerging trend ... are investing in R&D to develop new and advanced ... biomaterial implants. The introduction of third-generation orthopedic biomaterials such ... drugs will increase the growth of the market in ... Biomaterials market to grow at a CAGR of ...
Breaking Medicine News(10 mins):Health News:Swift County-Benson Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Swift County-Benson Hospital Retains B. E. Smith to Recruit New CEO 3Health News:New Treatment May Prevent Diabetes After Pancreatitis Surgery 2Health News:New Treatment May Prevent Diabetes After Pancreatitis Surgery 3Health News:"The Millionaire's Brain" - A Review Examining Winter & Alvin's Training Course Released 2Health News:Gothic Arch Greenhouses provides the Answers to the Many Questions and Considerations of Greenhouse Ownership 2Health News:Gothic Arch Greenhouses provides the Answers to the Many Questions and Considerations of Greenhouse Ownership 3Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 2Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 3Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 4
... have developed the first genetically altered monkey model that ... according to a new study funded by the National ... understand this complex, devastating and incurable genetic disorder affecting ... advance of online publication edition of Nature, could lead ...
... could offer therapy option for cancer patients ... medical techniques, it may be possible to create replacement ... to cancer. , That,s the conclusion of U.S. researchers ... Replacement bladders made from intestinal tissue have proven successful ...
... Men who come to the hospital with pneumonia generally are ... over the next year, despite aggressive medical care, according to ... International Conference of the American Thoracic Society. Scientific sessions are ... well known that women live longer than men. We have ...
... post-traumatic stress disorder (PTSD) among caregivers of deceased ... than in the average population, according to researchers ... well as their perceptions of the transplant recipients ... presented at the American Thoracic Societys 2008 International ...
... Study finds mortality and survival rates equal for both ... Minimally-invasive laparoscopic surgery and open surgery for colon cancer ... from 12 international studies involving over 3,300 patients. ... afraid that laparoscopy might impair survival in colorectal cancer ...
... aftermath of central China,s,earthquake, up to 50,000 people ... 150,000 were injured. An estimated 10 million people ... their homes. With great sorrow for,these widespread losses ... US$30,000, for a total of US$50,000. With contributions ...
Cached Medicine News:Health News:Researchers develop first transgenic monkey model of Huntington's disease 2Health News:Replacement Bladder Grown From Body's Own Cells 2Health News:Men at increased risk of death from pneumonia compared to women 2Health News:Depression and PTSD symptoms in caregivers of lung transplant patients 2Health News:Outcomes Similar for Laparoscopic, Open Colon Cancer Surgeries 2Health News:Supreme Master Ching Hai International Association Delivering US$160,000 in Aid to Earthquake Survivors in China 2
... Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope provides a new ... The latest in Fujinon engineering combines ... guide, and a wide 90 degree field ... distal tip diameter. In addition, the ...
... Tip Laryngoscopes are the most ... The articulating tip aids during ... improved view of epiglottis. Available ... styles. We guarantee your complete ...
German Style MacIntosh Fiber Optic Blade Laryngoscopes...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: